vs
Protalix BioTherapeutics, Inc.（PLX）与SOLESENCE, INC.（SLSN）财务数据对比。点击上方公司名可切换其他公司
SOLESENCE, INC.的季度营收约是Protalix BioTherapeutics, Inc.的1.4倍（$12.5M vs $9.1M），SOLESENCE, INC.净利率更高（1.3% vs -60.3%，领先61.6%），SOLESENCE, INC.同比增速更快（-0.7% vs -49.9%），过去两年SOLESENCE, INC.的营收复合增速更高（12.5% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
PLX vs SLSN — 直观对比
营收规模更大
SLSN
是对方的1.4倍
$9.1M
营收增速更快
SLSN
高出49.3%
-49.9%
净利率更高
SLSN
高出61.6%
-60.3%
两年增速更快
SLSN
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $12.5M |
| 净利润 | $-5.5M | $163.0K |
| 毛利率 | 49.4% | 27.5% |
| 营业利润率 | -51.1% | 1.5% |
| 净利率 | -60.3% | 1.3% |
| 营收同比 | -49.9% | -0.7% |
| 净利润同比 | -184.8% | 129.2% |
| 每股收益（稀释后） | $-0.06 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXSLSN
| Q4 25 | $9.1M | $12.5M | ||
| Q3 25 | $17.9M | $14.6M | ||
| Q2 25 | $15.7M | $20.4M | ||
| Q1 25 | $10.1M | $14.6M | ||
| Q4 24 | $18.2M | $12.6M | ||
| Q3 24 | $18.0M | $16.9M | ||
| Q2 24 | $13.5M | $13.0M | ||
| Q1 24 | — | $9.9M |
净利润PLXSLSN
| Q4 25 | $-5.5M | $163.0K | ||
| Q3 25 | $2.4M | $-1.1M | ||
| Q2 25 | $164.0K | $2.7M | ||
| Q1 25 | $-3.6M | $80.0K | ||
| Q4 24 | $6.5M | $-559.0K | ||
| Q3 24 | $3.2M | $3.0M | ||
| Q2 24 | $-2.2M | $856.0K | ||
| Q1 24 | — | $893.0K |
毛利率PLXSLSN
| Q4 25 | 49.4% | 27.5% | ||
| Q3 25 | 53.4% | 23.1% | ||
| Q2 25 | 62.5% | 28.9% | ||
| Q1 25 | 19.1% | 23.1% | ||
| Q4 24 | 78.7% | 22.0% | ||
| Q3 24 | 53.4% | 36.2% | ||
| Q2 24 | 29.8% | 28.7% | ||
| Q1 24 | — | 36.3% |
营业利润率PLXSLSN
| Q4 25 | -51.1% | 1.5% | ||
| Q3 25 | 11.9% | -5.4% | ||
| Q2 25 | 7.5% | 9.4% | ||
| Q1 25 | -41.0% | 1.8% | ||
| Q4 24 | 39.6% | -1.8% | ||
| Q3 24 | 22.2% | 19.0% | ||
| Q2 24 | -18.0% | 8.0% | ||
| Q1 24 | — | 11.3% |
净利率PLXSLSN
| Q4 25 | -60.3% | 1.3% | ||
| Q3 25 | 13.2% | -7.7% | ||
| Q2 25 | 1.0% | 13.1% | ||
| Q1 25 | -35.8% | 0.5% | ||
| Q4 24 | 35.6% | -4.4% | ||
| Q3 24 | 18.0% | 18.1% | ||
| Q2 24 | -16.4% | 6.6% | ||
| Q1 24 | — | 9.0% |
每股收益（稀释后）PLXSLSN
| Q4 25 | $-0.06 | $0.00 | ||
| Q3 25 | $0.03 | $-0.02 | ||
| Q2 25 | $0.00 | $0.04 | ||
| Q1 25 | $-0.05 | $0.00 | ||
| Q4 24 | $0.10 | $0.00 | ||
| Q3 24 | $0.03 | $0.04 | ||
| Q2 24 | $-0.03 | $0.01 | ||
| Q1 24 | — | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $1.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $17.6M |
| 总资产 | $82.3M | $50.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXSLSN
| Q4 25 | $14.7M | $1.3M | ||
| Q3 25 | $13.6M | $429.0K | ||
| Q2 25 | $17.9M | $4.1M | ||
| Q1 25 | $19.5M | $1.8M | ||
| Q4 24 | $19.8M | $1.4M | ||
| Q3 24 | $27.4M | $2.9M | ||
| Q2 24 | $23.4M | $2.4M | ||
| Q1 24 | — | $2.0M |
股东权益PLXSLSN
| Q4 25 | $48.2M | $17.6M | ||
| Q3 25 | $52.9M | $17.2M | ||
| Q2 25 | $49.9M | $18.2M | ||
| Q1 25 | $45.2M | $15.2M | ||
| Q4 24 | $43.2M | $14.9M | ||
| Q3 24 | $32.4M | $15.2M | ||
| Q2 24 | $28.6M | $11.9M | ||
| Q1 24 | — | $5.0M |
总资产PLXSLSN
| Q4 25 | $82.3M | $50.1M | ||
| Q3 25 | $82.3M | $54.0M | ||
| Q2 25 | $78.5M | $60.0M | ||
| Q1 25 | $73.9M | $57.0M | ||
| Q4 24 | $73.4M | $50.0M | ||
| Q3 24 | $61.6M | $48.0M | ||
| Q2 24 | $91.5M | $40.8M | ||
| Q1 24 | — | $38.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $1.8M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | — |
| 自由现金流率自由现金流/营收 | 17.8% | — |
| 资本支出强度资本支出/营收 | 4.4% | — |
| 现金转化率经营现金流/净利润 | — | 11.16× |
| 过去12个月自由现金流最近4个季度 | $-13.6M | — |
8季度趋势，按日历期对齐
经营现金流PLXSLSN
| Q4 25 | $2.0M | $1.8M | ||
| Q3 25 | $-3.7M | $-2.5M | ||
| Q2 25 | $-5.2M | $-654.0K | ||
| Q1 25 | $-5.1M | $-7.2M | ||
| Q4 24 | $4.0M | $2.2M | ||
| Q3 24 | $4.1M | $4.2M | ||
| Q2 24 | $-3.6M | $-565.0K | ||
| Q1 24 | — | $-3.9M |
自由现金流PLXSLSN
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | $-404.0K | ||
| Q3 24 | $4.0M | $2.8M | ||
| Q2 24 | $-3.8M | $-1.0M | ||
| Q1 24 | — | $-3.9M |
自由现金流率PLXSLSN
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | -3.2% | ||
| Q3 24 | 22.4% | 16.6% | ||
| Q2 24 | -28.1% | -8.0% | ||
| Q1 24 | — | -39.9% |
资本支出强度PLXSLSN
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | 20.6% | ||
| Q3 24 | 0.5% | 8.3% | ||
| Q2 24 | 1.3% | 3.7% | ||
| Q1 24 | — | 0.9% |
现金转化率PLXSLSN
| Q4 25 | — | 11.16× | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SLSN
暂无分部数据
